Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib in AML and MDS
NCT02488408Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Oct 2014
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of bemcentinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by BerGenBio ASA. Started Oct 2014; status: completed.
02
Drugs
bemcentinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02488408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488408.